Dosimetry and radioimmunotherapy of non-Hodgkin's lymphoma [5]

Journal of Nuclear Medicine

Volumn 45, Issue 12, 2004, Pages 2126-2127

  Postema, Ernst J ^a  

^a CATHARINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; EPRATUZUMAB; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RADIOISOTOPE; TECHNETIUM 99M; YTTRIUM;

ANTIGEN EXPRESSION; BODY SURFACE; BODY WEIGHT; BONE MARROW; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; DOSIMETRY; HUMAN; ISOTOPE LABELING; LETTER; NONHODGKIN LYMPHOMA; PATIENT ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SCINTIGRAPHY; TREATMENT RESPONSE; IMMUNOLOGY; NOTE; RADIATION DOSE;

HUMANS; LYMPHOMA, NON-HODGKIN; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 16644362628     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (7)

1. Britton KE. Radioimmunotherapy of non-Hodgkin's lymphoma [letter]. J Nucl Med. 2004;45:924-925.
2. Postema EJ, Boerman OC, Oyen WJG, Raemaekers JMM, Corstens FHM. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur J Nucl Med. 2001;28:1725-1735.
3. 186Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cancer Res. 2003;9:3995s-4002s.
4. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39:181-194.
5. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
6. 90Y-DOTA humanized anti-CD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003;44:2000 -2018.
7. Hindorf C, Lindén O, Stenberg L, Tennvall J. Strand SE. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. Clin Cancer Res. 2003;9:4003s-4006s.